Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.

ABSTRACT: Hepatocellular carcinoma is a cancer with increasing incidence and largely refractory to current anticancer drugs. Since Sorafenib, a multikinase inhibitor has shown modest efficacy in advanced hepatocellular carcinoma additional treatments are highly needed. Protein phosphorylation via kinases is an important post-translational modification to regulate cell homeostasis including proliferation and apoptosis. Therefore kinases are valuable targets in cancer therapy. To this end we performed 2D differential gel electrophoresis and mass spectrometry analysis of phosphoprotein-enriched lysates of tumor and corresponding non-tumorous liver samples to detect differentially abundant phosphoproteins to screen for novel kinases as potential drug targets. We identified 34 differentially abundant pro

SUBMITTER: Pott LL 

PROVIDER: S-EPMC5355317 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature